Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Disodium ascorbyl phytostanol phosphate (FM-VP4) is a synthetic, water-soluble derivative of plant stanols, specifically sitostanol and campestanol, each covalently linked to ascorbic acid via a phosphodiester bond. Developed to improve solubility and efficacy over traditional plant sterols/stanols, FM-VP4 acts primarily as a cholesterol absorption inhibitor. It reduces intestinal cholesterol uptake by competing with dietary and biliary cholesterol for absorption in the gut. Preclinical studies demonstrated potent cholesterol-lowering effects without significant toxicity, while clinical trials showed that doses up to 800 mg/day are safe and well tolerated for at least four weeks. The maximum LDL-cholesterol reduction was observed at 400 mg/day. FM-VP4 also exhibits potential benefits in reducing plasma triglycerides, weight gain, and exerting anti-atherosclerotic effects[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on disodium ascorbyl phytostanol phosphate.